JP2007527851A - 乾癬の治療薬を製造するためのカハラリド化合物の使用 - Google Patents
乾癬の治療薬を製造するためのカハラリド化合物の使用 Download PDFInfo
- Publication number
- JP2007527851A JP2007527851A JP2006502323A JP2006502323A JP2007527851A JP 2007527851 A JP2007527851 A JP 2007527851A JP 2006502323 A JP2006502323 A JP 2006502323A JP 2006502323 A JP2006502323 A JP 2006502323A JP 2007527851 A JP2007527851 A JP 2007527851A
- Authority
- JP
- Japan
- Prior art keywords
- kahalalide
- kahalalide compound
- compound
- day
- psoriasis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Description
1から7個、特に1から3個、より特別には1または2、最も特別には1個の、元となる化合物のアミノ酸と同じではないアミノ酸;
1から10個、特に1から6個、より特別には1から3個、最も特別には1または2個の、元となる化合物の側鎖アシル基における追加のメチレン基;
1から10個、特に1から6個、より特別には1から3個、最も特別には1または2個の、元となる化合物の側鎖アシル基から削除されたメチレン基;
1から6個、特に1から3個、より特別には1または3個の、元となる化合物の側鎖アシル基に追加された、または前記アシル基から削除された置換基。
〔実施例〕
Claims (24)
- 真皮細胞の過剰増殖を含む皮膚疾患を治療するための医薬の製造におけるカハラリド化合物の使用。
- 前記皮膚疾患が乾癬である、請求項1に記載のカハラリド化合物の使用。
- 前記カハラリド化合物がカハラリドF、4-メチルヘキシルアナログまたはそれらの混合物である、請求項1または2に記載のカハラリド化合物の使用。
- 前記カハラリド化合物がカハラリドFである、請求項3に記載のカハラリド化合物の使用。
- 前記カハラリド化合物を1種もしくは複数のその他の薬物または治療法と組み合わせて使用して、併用療法を提供する、請求項1〜4のいずれか一項に記載のカハラリド化合物の使用。
- 前記カハラリド化合物を1200μg/m2/日と320μg/m2/日の間の用量レベルで投与する、請求項1〜5のいずれか一項に記載のカハラリド化合物の使用。
- 前記用量レベルが800μg/m2/日と500μg/m2/日の間である、請求項6に記載のカハラリド化合物の使用。
- 前記用量レベルが650μg/m2/日である、請求項7に記載のカハラリド化合物の使用。
- 前記カハラリド化合物を1から4週間の周期で静脈内投与する、請求項1〜8のいずれか一項に記載のカハラリド化合物の使用。
- 前記カハラリド化合物を週1回の周期で投与する、請求項9に記載のカハラリド化合物の使用。
- 有効で、毒性のない量のカハラリド化合物を哺乳動物に投与することを含む、哺乳動物の真皮細胞の過剰増殖を含む皮膚疾患を治療する方法。
- 前記皮膚疾患が乾癬である、請求項11に記載の方法。
- 前記哺乳動物はヒト患者である、請求項11または12に記載の方法。
- 前記カハラリド化合物がカハラリドF、4-メチルヘキシルアナログまたはそれらの混合物である、請求項11から13のいずれか一項に記載の方法。
- 前記カハラリド化合物がカハラリドFである、請求項14に記載の方法。
- 前記カハラリド化合物を1種もしくは複数のその他の薬物または治療法と組み合わせて使用して、併用療法を提供する、請求項1〜15のいずれか一項に記載の方法。
- 前記カハラリド化合物を1200μg/m2/日と320μg/m2/日の間の用量レベルで投与する、請求項11〜16のいずれか一項に記載の方法。
- 前記用量レベルが800μg/m2/日と500μg/m2/日の間である、請求項17に記載の方法。
- 前記用量レベルが650μg/m2/日である、請求項18に記載の方法。
- 前記カハラリド化合物を1から4週間の周期で静脈内投与する、請求項11〜19のいずれか一項に記載の方法。
- 前記カハラリド化合物を週1回の周期で投与する、請求項20に記載の方法。
- 真皮細胞の過剰増殖を含む皮膚疾患の治療のための、カハラリド化合物および薬剤として許容される担体を含む医薬組成物。
- 前記皮膚疾患が乾癬である、請求項22に記載の医薬組成物。
- カハラリド化合物を投与するための印刷された説明書、および少なくとも1周期用の投与単位の前記カハラリド化合物の供給物を含む、乾癬治療のために前記カハラリド化合物を投与するための医療用キット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0304367.6A GB0304367D0 (en) | 2003-02-26 | 2003-02-26 | Methods for treating psoriasis |
GB0304367.6 | 2003-02-26 | ||
PCT/GB2004/000757 WO2004075910A1 (en) | 2003-02-26 | 2004-02-26 | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007527851A true JP2007527851A (ja) | 2007-10-04 |
JP4800194B2 JP4800194B2 (ja) | 2011-10-26 |
Family
ID=9953685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006502323A Expired - Fee Related JP4800194B2 (ja) | 2003-02-26 | 2004-02-26 | 乾癬の治療薬を製造するためのカハラリド化合物の使用 |
Country Status (17)
Country | Link |
---|---|
US (2) | US7323444B2 (ja) |
EP (1) | EP1596879B1 (ja) |
JP (1) | JP4800194B2 (ja) |
AT (1) | ATE492285T1 (ja) |
AU (1) | AU2004216443B2 (ja) |
CA (1) | CA2516458C (ja) |
CY (1) | CY1111353T1 (ja) |
DE (1) | DE602004030661D1 (ja) |
DK (1) | DK1596879T3 (ja) |
ES (1) | ES2358018T3 (ja) |
GB (1) | GB0304367D0 (ja) |
MX (1) | MXPA05009029A (ja) |
NZ (1) | NZ541493A (ja) |
PT (1) | PT1596879E (ja) |
RU (1) | RU2356908C2 (ja) |
SI (1) | SI1596879T1 (ja) |
WO (1) | WO2004075910A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0002952D0 (en) | 2000-02-09 | 2000-03-29 | Pharma Mar Sa | Process for producing kahalalide F compounds |
GB0304367D0 (en) * | 2003-02-26 | 2003-04-02 | Pharma Mar Sau | Methods for treating psoriasis |
US7507708B2 (en) | 2003-02-26 | 2009-03-24 | Pharma Mar, S.A.U. | Antitumoral compounds |
GB0321066D0 (en) * | 2003-09-09 | 2003-10-08 | Pharma Mar Sau | New antitumoral compounds |
KR20100099128A (ko) * | 2007-10-19 | 2010-09-10 | 파르마 마르 에스.에이. | 개선된 항암치료 |
US20100323021A1 (en) * | 2008-01-30 | 2010-12-23 | Pharma Mar, S.A. | Antitumoral treatments |
RU2010140890A (ru) * | 2008-03-07 | 2012-04-20 | Фарма Мар, С.А. (Es) | Улучшенные способы противоопухолевого лечения |
JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0770185A (ja) * | 1993-02-03 | 1995-03-14 | Pharma Mar Sa | 細胞毒性および抗ウイルス性を有する化合物 |
WO2002036145A2 (en) * | 2000-10-31 | 2002-05-10 | Pharma Mar, S.A. | Kahalalide f formulation |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
US4943533A (en) * | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
JPS6178719A (ja) * | 1984-09-25 | 1986-04-22 | Tanabe Seiyaku Co Ltd | 総合輸液剤 |
GR870129B (en) * | 1987-01-27 | 1987-02-04 | Giatzidis Ippokratis | Stable bicarbonate - glycylglycine dialysate for hemodialysis and peritoneal dialysis |
US4853388A (en) * | 1987-05-15 | 1989-08-01 | Pearlman Dale L | Method for treating psoriasis with cytotoxic agents |
US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
CZ282603B6 (cs) * | 1991-03-06 | 1997-08-13 | Merck Patent Gesellschaft Mit Beschränkter Haftun G | Humanizované a chimerické monoklonální protilátky |
US5849704A (en) * | 1991-12-20 | 1998-12-15 | Novo Nordisk A/S | Pharmaceutical formulation |
GB9300059D0 (en) * | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
US6274551B1 (en) * | 1994-02-03 | 2001-08-14 | Pharmamar, S.A. | Cytotoxic and antiviral compound |
US5932189A (en) * | 1994-07-29 | 1999-08-03 | Diatech, Inc. | Cyclic peptide somatostatin analogs |
US5705511A (en) * | 1994-10-14 | 1998-01-06 | Cephalon, Inc. | Fused pyrrolocarbazoles |
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
JP3927248B2 (ja) | 1995-07-11 | 2007-06-06 | 第一製薬株式会社 | Hgf凍結乾燥製剤 |
EP0912559B1 (en) * | 1996-07-13 | 2002-11-06 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US6489136B1 (en) * | 1997-05-09 | 2002-12-03 | The General Hospital Corporation | Cell proliferation related genes |
RS49779B (sr) * | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
GB9803448D0 (en) | 1998-02-18 | 1998-04-15 | Pharma Mar Sa | Pharmaceutical formulation |
US6200598B1 (en) * | 1998-06-18 | 2001-03-13 | Duke University | Temperature-sensitive liposomal formulation |
US6344455B1 (en) * | 1998-11-19 | 2002-02-05 | Warner-Lambert Company | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, and irreversible inhibitor of tyrosine kinases |
US7311924B2 (en) * | 1999-04-01 | 2007-12-25 | Hana Biosciences, Inc. | Compositions and methods for treating cancer |
UA74803C2 (uk) * | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
GB0002952D0 (en) * | 2000-02-09 | 2000-03-29 | Pharma Mar Sa | Process for producing kahalalide F compounds |
US7056502B2 (en) * | 2000-04-28 | 2006-06-06 | The Trustees Of The University Of Pennsylvania | Recombinant aav vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids |
US6440465B1 (en) * | 2000-05-01 | 2002-08-27 | Bioderm, Inc. | Topical composition for the treatment of psoriasis and related skin disorders |
US20050054555A1 (en) * | 2001-10-19 | 2005-03-10 | Jose Jimeno | Kahalalide compounds for use in cancer therapy |
WO2003033012A1 (en) | 2001-10-19 | 2003-04-24 | Pharma Mar, S.A. | Kahalalide compounds for use in cancer therapy |
GB0304367D0 (en) * | 2003-02-26 | 2003-04-02 | Pharma Mar Sau | Methods for treating psoriasis |
EP1572726B1 (en) | 2002-10-18 | 2010-12-08 | Pharma Mar, S.A.U. | 4-methylhexanoic kahalalide f compound |
US7507708B2 (en) * | 2003-02-26 | 2009-03-24 | Pharma Mar, S.A.U. | Antitumoral compounds |
GB0321066D0 (en) | 2003-09-09 | 2003-10-08 | Pharma Mar Sau | New antitumoral compounds |
GB0408958D0 (en) | 2004-04-22 | 2004-05-26 | Pharma Mar Sa | Convergent synthesis for kahalalide compounds |
-
2003
- 2003-02-26 GB GBGB0304367.6A patent/GB0304367D0/en not_active Ceased
- 2003-10-20 RU RU2005115102/04A patent/RU2356908C2/ru not_active IP Right Cessation
-
2004
- 2004-02-26 SI SI200431619T patent/SI1596879T1/sl unknown
- 2004-02-26 PT PT04714847T patent/PT1596879E/pt unknown
- 2004-02-26 DK DK04714847.3T patent/DK1596879T3/da active
- 2004-02-26 AU AU2004216443A patent/AU2004216443B2/en not_active Ceased
- 2004-02-26 DE DE602004030661T patent/DE602004030661D1/de not_active Expired - Lifetime
- 2004-02-26 CA CA2516458A patent/CA2516458C/en not_active Expired - Fee Related
- 2004-02-26 EP EP04714847A patent/EP1596879B1/en not_active Expired - Lifetime
- 2004-02-26 WO PCT/GB2004/000757 patent/WO2004075910A1/en active Application Filing
- 2004-02-26 NZ NZ541493A patent/NZ541493A/en not_active IP Right Cessation
- 2004-02-26 JP JP2006502323A patent/JP4800194B2/ja not_active Expired - Fee Related
- 2004-02-26 MX MXPA05009029A patent/MXPA05009029A/es active IP Right Grant
- 2004-02-26 AT AT04714847T patent/ATE492285T1/de active
- 2004-02-26 ES ES04714847T patent/ES2358018T3/es not_active Expired - Lifetime
- 2004-02-26 US US10/546,758 patent/US7323444B2/en not_active Expired - Fee Related
-
2007
- 2007-12-04 US US11/950,144 patent/US20080090757A1/en not_active Abandoned
-
2011
- 2011-03-22 CY CY20111100314T patent/CY1111353T1/el unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0770185A (ja) * | 1993-02-03 | 1995-03-14 | Pharma Mar Sa | 細胞毒性および抗ウイルス性を有する化合物 |
WO2002036145A2 (en) * | 2000-10-31 | 2002-05-10 | Pharma Mar, S.A. | Kahalalide f formulation |
Also Published As
Publication number | Publication date |
---|---|
PT1596879E (pt) | 2011-02-23 |
DK1596879T3 (da) | 2011-04-11 |
ATE492285T1 (de) | 2011-01-15 |
DE602004030661D1 (de) | 2011-02-03 |
ES2358018T3 (es) | 2011-05-04 |
WO2004075910A1 (en) | 2004-09-10 |
MXPA05009029A (es) | 2005-11-23 |
NZ541493A (en) | 2008-07-31 |
AU2004216443B2 (en) | 2009-03-19 |
US7323444B2 (en) | 2008-01-29 |
AU2004216443A1 (en) | 2004-09-10 |
US20080090757A1 (en) | 2008-04-17 |
GB0304367D0 (en) | 2003-04-02 |
CA2516458C (en) | 2012-11-27 |
RU2005115102A (ru) | 2006-02-27 |
SI1596879T1 (sl) | 2011-07-29 |
EP1596879B1 (en) | 2010-12-22 |
EP1596879A1 (en) | 2005-11-23 |
US20070032412A1 (en) | 2007-02-08 |
JP4800194B2 (ja) | 2011-10-26 |
CA2516458A1 (en) | 2004-09-10 |
RU2356908C2 (ru) | 2009-05-27 |
CY1111353T1 (el) | 2015-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60029829T2 (de) | Zelldurchlässige peptide zur inhibierung von entzündungsreaktionen und deren verwendung | |
US20080090757A1 (en) | Kahalalide Compositions for the Treatment of Psoriasis | |
US9938320B2 (en) | Peptides for promoting angiogenesis and use thereof | |
US11414474B2 (en) | Long-acting adrenomedullin derivatives | |
JPH07506113A (ja) | 前立腺癌,胃癌および乳癌に関連する腫瘍を抑制するための医薬製剤 | |
US20230226145A1 (en) | Mutant Peptides And Methods Of Treating Subjects Using The Same | |
US20100330093A1 (en) | Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4) | |
KR100191381B1 (ko) | 스테로이드 요법에 의한 부작용을 경감 또는 예방하고 코르티코스테로이드 요법을 안전화시키기 위한 조성물 | |
JP2002502369A (ja) | 胃腸管上部の機能を強化する方法 | |
NZ212691A (en) | Pharmaceutical composition containing refined detoxified endotoxin | |
JPH0667832B2 (ja) | 腫瘍性疾患の治療に用いるプログルミド含有医薬組成物 | |
US20180125933A1 (en) | Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide | |
AU2021200731B2 (en) | Pro-drug peptide with improved pharmaceutical properties | |
JP3520084B2 (ja) | 多発性硬化症を含めた炎症の治療におけるペプチドt及びその関連ペプチド類 | |
EP1435990A1 (en) | Kahalalide compounds for use in cancer therapy | |
AU2002334203A1 (en) | Kahalalide compounds for use in cancer therapy | |
KR20180102091A (ko) | 당뇨병의 치료를 위한 약제학적 제제 | |
WO2016195476A1 (en) | Treatment of cardiac arrhythmias | |
JPH09506115A (ja) | 細胞毒性薬の副作用を軽減するためのトランスフェリン組成物 | |
US20210228681A1 (en) | Compositions and methods for treating glioblastoma | |
WO2014075137A1 (en) | Peptides incorporating amino-substituted lactams for treatment of retinopathy | |
JP2002080395A (ja) | 心筋傷害処置剤 | |
JPH01193231A (ja) | 抗腫瘍剤 | |
JPH10279498A (ja) | 慢性関節リウマチ治療剤 | |
JPH0543479A (ja) | 肝炎治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100406 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100617 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100624 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100805 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100831 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101129 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110111 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110427 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20110518 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110705 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110803 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140812 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |